Aulitzky W E, Grosse-Wilde H, Westhoff U, Tilg H, Aulitzky W, Gastl G, Herold M, Huber C
Third Department of Medicine, Johannes Gutenberg University, Mainz, Germany.
Clin Exp Immunol. 1991 Nov;86(2):236-9. doi: 10.1111/j.1365-2249.1991.tb05802.x.
In order to investigate serum levels of soluble HLA class I antigens after single injection of various doses of recombinant IFN-gamma (rIFN-gamma) and to correlate the changes observed to beta-2-microglobulin serum levels, we studied five patients with metastasizing renal cell carcinoma. Each patient received three treatment cycles of 10, 100 and 500 micrograms rIFN-gamma three times at weekly intervals. The treatment cycles were separated by a therapy-free interval of 2 weeks. The order of dose levels was randomly assigned to each patient. Serum levels of soluble HLA class I proteins were measured by an ELISA in samples drawn immediately before and 4, 24, 48, 72 and 168 h after each administration of rIFN-gamma. Beta-2-microglobulin was assessed in parallel using a commercially available radioimmunoassay. Significant induction of soluble HLA class I protein serum levels was observed after treatment with 100 and 500 micrograms rIFN-gamma. The increments peaked after 2-4 days and remained elevated for up to more than 7 days. A significant correlation between increments of soluble HLA class I proteins and beta-2-microglobulin was observed. We conclude that measurement of soluble HLA serum levels is practical for monitoring induction of HLA class I synthesis in patients treated with rIFN-gamma. The correlation observed between induction of beta-2-microglobulin and soluble HLA class I proteins indicates that measurement of beta-2-microglobulin might be sufficient for the biological response monitoring in clinical studies.
为了研究单次注射不同剂量重组干扰素-γ（rIFN-γ）后可溶性 HLA-I 类抗原的血清水平，并将观察到的变化与β2-微球蛋白血清水平相关联，我们研究了 5 例转移性肾细胞癌患者。每位患者接受三个治疗周期，分别为每周三次注射 10、100 和 500 微克 rIFN-γ。治疗周期之间间隔 2 周的无治疗期。剂量水平的顺序随机分配给每位患者。在每次注射 rIFN-γ之前以及注射后 4、24、48、72 和 168 小时采集的样本中，通过酶联免疫吸附测定法（ELISA）测量可溶性 HLA-I 类蛋白的血清水平。使用市售放射免疫测定法并行评估β2-微球蛋白。在用 100 和 500 微克 rIFN-γ治疗后，观察到可溶性 HLA-I 类蛋白血清水平有显著诱导。增量在 2 - 4 天后达到峰值，并持续升高长达 7 天以上。观察到可溶性 HLA-I 类蛋白增量与β2-微球蛋白之间存在显著相关性。我们得出结论，测量可溶性 HLA 血清水平对于监测接受 rIFN-γ治疗患者的 HLA-I 类合成诱导是可行的。观察到的β2-微球蛋白诱导与可溶性 HLA-I 类蛋白之间的相关性表明，在临床研究中测量β2-微球蛋白可能足以进行生物学反应监测。
